Literature DB >> 27161059

First pass dual input volume CT-perfusion of lung lesions: The influence of the CT- value range settings on the perfusion values of benign and malignant entities.

Dennis Bohlsen1, Emina Talakic1, Gerald A Fritz2, Franz Quehenberger3, Manfred Tillich4, Helmut Schoellnast5.   

Abstract

OBJECTIVE: To assess the influence of the lower threshold for segmentation of the volume of interest on the perfusion values in first-pass dual input volume CT-perfusion of lung lesions.
MATERIALS AND METHODS: Dual input maximum slope volume CT-perfusion was performed in 48 patients (mean age±standard deviation [SD], 68±10years; range, 46-87 years) who underwent subsequent CT-guided biopsy to evaluate a lung lesion. Using commercial perfusion software, a lower and upper threshold was set for determination of the CT-value range, which again determined the volume of interest for perfusion calculation. The pulmonary arterial flow (PAF), bronchial arterial flow (BAF), and perfusion index (PI; PAF/(PAF+BAF)) were calculated at following pre contrast CT value range settings: -80 to 150HU (setting 1), -200 to 150HU (setting 2), -300 to 150HU (setting 3), and -500 to 150HU (setting 4). Perfusion parameters were compared between benign (n, 15) and malignant (n, 33) lesions for each setting. Intraobserver- and interobserver reliability were calculated for setting 4.
RESULTS: Median PAF was significantly higher in malignant lesions than in benign lesions for all settings (53-96 versus 29-62mL/min/100mL, P<0.05). There was no significant difference in BAF between malignant and benign lesions. Median PAF of all lesions was significantly influenced by the CT value range setting (P<0.05), whereas the values increased from setting 1 to 4. Intraobserver analysis as well as interobserver analysis of PAF at setting 4 showed excellent reliability (Cronbach's alpha 0.98 and 0.95, respectively, P<0.01).
CONCLUSION: PAF derived from first-pass dual-input maximum slope volume CT perfusion is statistically significantly higher in malignant than in benign lesion, whereas the measurements are influenced by the lower threshold of the CT value range setting. This has to be considered when using cutoff values provided in the literature for differentiation between benign and malignant lung lesions.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Lung neoplasms; Perfusion; Volume computed tomography

Mesh:

Substances:

Year:  2016        PMID: 27161059     DOI: 10.1016/j.ejrad.2016.03.013

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  5 in total

1.  Multislice Analysis of Blood Flow Values in CT Perfusion Studies of Lung Cancer.

Authors:  Silvia Malavasi; Domenico Barone; Giampaolo Gavelli; Alessandro Bevilacqua
Journal:  Biomed Res Int       Date:  2017-01-10       Impact factor: 3.411

2.  Pulmonary lesions: correlative study of dynamic triple-phase enhanced CT perfusion imaging with tumor angiogenesis and vascular endothelial growth factor expression.

Authors:  Mingyue Zou; Zhenhua Zhao; Bingqian Zhang; Haijia Mao; Yanan Huang; Cheng Wang
Journal:  BMC Med Imaging       Date:  2021-10-30       Impact factor: 1.930

3.  Comparison of Spectral and Perfusion Computed Tomography Imaging in the Differential Diagnosis of Peripheral Lung Cancer and Focal Organizing Pneumonia.

Authors:  Liangna Deng; Guojin Zhang; Xiaoqiang Lin; Tao Han; Bin Zhang; Mengyuan Jing; Junlin Zhou
Journal:  Front Oncol       Date:  2021-10-27       Impact factor: 6.244

4.  Association Between the Incidence of Pancreatic Fistula After Pancreaticoduodenectomy and the Degree of Pancreatic Fibrosis.

Authors:  Yong Deng; Baixiong Zhao; Meiwen Yang; Chuanhong Li; Leida Zhang
Journal:  J Gastrointest Surg       Date:  2018-01-12       Impact factor: 3.452

5.  Low-dose spectral CT perfusion imaging of lung cancer quantitative analysis in different pathological subtypes.

Authors:  Mai-Lin Chen; Yi-Yuan Wei; Xiao-Ting Li; Li-Ping Qi; Ying-Shi Sun
Journal:  Transl Cancer Res       Date:  2021-06       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.